Facial disfigurement: is it in the eye of the beholder? A study in patients with Graves' ophthalmopathy

被引:23
|
作者
Terwee, CB
Dekker, FW
Bonsel, GJ
Heisterkamp, SH
Prummel, MF
Baldeschi, L
Wiersinga, WM
机构
[1] VU Med Ctr, Inst Res Extramural Med, EMGO Inst, NL-1081 BT Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Dept Endocrinol & Metab, NL-1105 AZ Amsterdam, Netherlands
[4] Univ Amsterdam, Acad Med Ctr, Orbital Ctr, NL-1105 AZ Amsterdam, Netherlands
[5] Univ Amsterdam, Acad Med Ctr, Dept Publ Hlth, NL-1105 AZ Amsterdam, Netherlands
[6] Leiden Univ, Med Ctr, Dept Clin Epidemiol, NL-2300 RA Leiden, Netherlands
关键词
D O I
10.1046/j.1365-2265.2003.01695.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES The importance of facial disfigurement in many diseases necessitates a reliable and valid measure of disfigurement severity for clinical studies. The hypothesis is that a universal concept of disfigurement exists and can be measured in a reliable way. The objectives of this study were to investigate if persons, in particular patients and physicians, can agree on facial disfigurement severity; and to determine the relative contribution of predefined clinical characteristics of patients with Graves' ophthalmopathy (GO) to the overall rating of facial disfigurement severity. DESIGN A panel study was carried out in four different panels, each consisting of four members. PATIENTS We randomly selected 100 slide pairs of GO patients from four available study populations, involving mild, moderate and severe GO patients (mean age 49 years, 76% female) who were treated with either radiotherapy, sham-irradiation, prednisone or orbital decompression. MEASUREMENTS All panel members individually scored the disfigurement severity of 100 GO patients shown on standardized slides on a Visual Analog Scale. In total, 1600 ratings were collected. We calculated within- and between-panel agreement of disfigurement severity and identified determinants of disfigurement. RESULTS Agreement within a panel varied from 0.65 to 0.79 and was highest within the panel of ophthalmologists. Between-panel agreement was 0.67 and was highest between ophthalmologists and laypersons. Compared with the global average, patients overrated and endocrinologists underrated disfigurement severity. Female panellists rated the patients, on average, more disfigured than male panellists. Important determinants of disfigurement were eyelid retraction, severe eyelid swelling and proptosis. Their relative importance was consistent across panels and in contrast to current measures of GO severity. CONCLUSION Facial disfigurement severity can be measured in a reliable way using panels of panellists. Except for some systematic differences between panellists, facial disfigurement does not seem to be in the eye of the beholder.
引用
收藏
页码:192 / 198
页数:7
相关论文
共 50 条
  • [31] Clinical Features of Graves' Ophthalmopathy and Impact of Enalapril on the Course of Mild Graves' Ophthalmopathy: A Pilot Study
    Ataabadi, Ghazal
    Dabbaghmanesh, Mohammad H.
    Owji, Naser
    Bakhshayeshkaram, Marzieh
    Montazeri-Najafabady, Nima
    ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, 2020, 20 (01) : 139 - 148
  • [32] Meeting the psychological needs of patients with facial disfigurement
    Bradbury, Eileen
    BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY, 2012, 50 (03): : 193 - 196
  • [33] SERUM IMMUNOGLOBULINS IN PATIENTS WITH GRAVES OPHTHALMOPATHY DIRECTED AGAINST UNIQUE DETERMINANTS OF PORCINE EYE MUSCLE
    AHMANN, A
    BAKER, JR
    WEETMAN, AP
    WARTOFSKY, L
    NUTMAN, T
    BURMAN, KD
    CLINICAL RESEARCH, 1986, 34 (02): : A420 - A420
  • [34] A retrospective study of clinical features and prognosis of patients with Graves' disease and ophthalmopathy
    Rui, Zhong Ying
    Yin, Xue
    Wang, Xuan
    Shen, Jie
    Zheng, Wei
    NUCLEAR MEDICINE COMMUNICATIONS, 2023, 44 (02) : 137 - 141
  • [35] Differential Therapeutic Response to Intravenous Glucocorticoid Therapy for Graves' Ophthalmopathy Patients with Bilateral Eye Disorder and Unilateral Eye Disorder
    Matsuzawa, Kazuhiko
    Izawa, Shoichiro
    Ohkura, Hiroko
    Nakanishi, Risa
    Sumi, Keisuke
    Shiochi, Hideki
    Fujioka, Youhei
    Yamamoto, Naoya
    Ohkura, Tsuyoshi
    Yoshida, Akio
    Shigemasa, Chiaki
    Kato, Masahiko
    Yamamoto, Kazuhiro
    Taniguchi, Shin-ichi
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [36] Is it reasonable to measure extraocular eye muscle enlargement in graves ophthalmopathy (GO): A MR relaxometry study
    Pauleit, DO
    Textor, HJ
    Keller, E
    Sommer, T
    Schild, HH
    RADIOLOGY, 1998, 209P : 348 - 348
  • [37] COMPUTED TOMOGRAPHY OF ORBIT IN PATIENTS WITH GRAVES OPHTHALMOPATHY
    ENZMANN, D
    KRISS, J
    MARSHALL, W
    ROSENTAL, R
    INVESTIGATIVE RADIOLOGY, 1975, 10 (05) : 451 - 451
  • [38] Ablative therapy for Graves' hyperthyroidism in patients with ophthalmopathy
    Lind, P
    ACTA MEDICA AUSTRIACA, 2001, 28 (04) : 107 - 109
  • [39] ANTIBODIES TO CHOLINESTERASE IN THE SERUM OF GRAVES OPHTHALMOPATHY PATIENTS
    SOREQ, H
    DREYFUS, P
    ZISLING, R
    ZAMIR, R
    ZAKUT, H
    LUDGATE, M
    ANNALES D ENDOCRINOLOGIE, 1987, 48 (02) : 131 - 131
  • [40] OPHTHALMOPATHIC IMMUNOGLOBULIN NOT DETECTED IN PATIENTS WITH GRAVES OPHTHALMOPATHY
    BJELKENKRANTZ, K
    KARLSSON, A
    MENDELHARTVIG, I
    TOTTERMAN, TH
    BRITISH MEDICAL JOURNAL, 1986, 292 (6535): : 1597 - 1597